Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)

Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)

Objectives: No previous studies specifically explored the switch from efavirenz to bictegravir (BIC)-containing three-drug antiretroviral regimens. This study aimed to evaluate the efficacy and safety outcomes of a treatment switch from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/...

Full description

Saved in:
Bibliographic Details
Main Authors: Roberta Gagliardini, Marta Camici, Simone Lanini, Rita Bellagamba, Sandrine Ottou, Maria Maddalena Plazzi, Alessandra Vergori, Valentina Mazzotta, Annalisa Mondi, Marisa Fusto, Jessica Paulicelli, Massimo Tempestilli, Carmela Pinnetti, Elisabetta Grilli, Ilaria Mastrorosa, Federico De Zottis, Giulia Del Duca, Andrea Antinori
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:International Journal of Infectious Diseases
Subjects:
ART optimization
Integrase strand transfer inhibitor
Antiretroviral therapy
ART-experienced
Bictegravir
EFV-based regimen
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971225001857
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S1201971225001857

Similar Items